Michael Newman

Company: Indaptus Therapeutics

Job title: Founder & Chief Scientific Officer

Seminars:

Hitting Multiple Immune System Targets with a Passively Targeted, Pulsed, Systemic Approach to Amplify Efficacy & Widen the Therapeutic Index 9:15 am

Taking advantage of multiple TLR/STING agonists, passive targeting and rapid clearance associated with bacteria Activation of both innate and adaptive anti-tumor immunity, tumor eradication and immunological memory in pre-clinical models Confirmation of a pulse-prime mechanism and update on a Phase 1 clinical trial with Decoy20Read more

day: Conference Day 2